These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36353778)

  • 1. Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.
    Murayama A; Hoshi M; Saito H; Kamamoto S; Tanaka M; Kawashima M; Mamada H; Kusumi E; Sapkota B; Shrestha S; Shrestha R; Bhandari D; Sawano T; Yamashita E; Tanimoto T; Ozaki A
    Respiration; 2022; 101(12):1088-1098. PubMed ID: 36353778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.
    Murayama A; Kamamoto S; Saito H; Yamada K; Bhandari D; Shoji I; Mamada H; Kawashima M; Yamashita E; Kusumi E; Sawano T; Sapkota B; Tanimoto T; Ozaki A
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019.
    Murayama A; Kamamoto S; Saito H; Ozaki A
    Sci Rep; 2023 May; 13(1):7425. PubMed ID: 37156855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019.
    Murayama A; Saito H; Kamamoto S; Shigeta H; Yamashita E; Tanimoto T; Ozaki A
    Int Urogynecol J; 2023 Jun; 34(6):1285-1292. PubMed ID: 36723634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019.
    Kamamoto S; Ozaki A; Murayama A
    Cureus; 2023 Aug; 15(8):e43633. PubMed ID: 37719565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019.
    Murayama A; Mamada H; Shigeta H; Yoshinaga T; Saito H; Yamashita E; Tanimoto T; Ozaki A
    J Clin Rheumatol; 2023 Apr; 29(3):118-125. PubMed ID: 36729793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Payments to Japanese Board-Certified Head and Neck Surgeons Between 2016 and 2019.
    Murayama A; Shigeta H; Kamamoto S; Yamashita E; Saito H; Sawano T; Bhandari D; Shrestha S; Kusumi E; Tanimoto T; Ozaki A
    OTO Open; 2023; 7(1):e31. PubMed ID: 36998569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020.
    Murayama A; Saito H; Tanimoto T; Ozaki A
    J Eval Clin Pract; 2023 Sep; 29(6):883-886. PubMed ID: 37283452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019.
    Murayama A; Kamamoto S; Kawashima M; Saito H; Yamashita E; Tanimoto T; Ozaki A
    BMJ Open; 2023 Apr; 13(4):e068237. PubMed ID: 37072354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan.
    Murayama A; Senoo Y
    BMC Med Ethics; 2024 Feb; 25(1):22. PubMed ID: 38378633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis.
    Ozaki A; Saito H; Onoue Y; Sawano T; Shimada Y; Somekawa Y; Tsuji A; Tanimoto T
    BMJ Open; 2019 Sep; 9(9):e028805. PubMed ID: 31494604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross-sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019.
    Kamamoto S; Murayama A; Kusumi E; Yoshida M; Saito H; Sawano T; Yamashita E; Tanimoto T; Ozaki A
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29891. PubMed ID: 35949170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nature and Trend of Pharmaceutical Payments to Japanese Board-Certified Neurologists Between 2016 and 2019: A Pre-emergence Analysis Amidst the Development of Next-Generation Alzheimer's Disease Drugs.
    Shrestha R; Saito H; Yamashita E; Shrestha S; Tanimoto T; Ozaki A
    Cureus; 2024 Feb; 16(2):e53848. PubMed ID: 38465045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan.
    Murayama A; Aizawa M; Byreddy KR; Higuchi K; Senoo Y
    J Am Heart Assoc; 2024 Apr; 13(8):e034506. PubMed ID: 38606773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan.
    Yamamoto K; Murayama A; Ozaki A; Saito H; Sawano T; Tanimoto T
    Int Urogynecol J; 2021 Feb; 32(2):443-451. PubMed ID: 33151353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
    Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
    Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.
    Sawano T; Ozaki A; Saito H; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 May; 2(5):e193817. PubMed ID: 31099864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan.
    Murayama A; Kugo H; Senoo Y
    BMJ Open; 2024 Jun; 14(6):e086396. PubMed ID: 38908845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017.
    Harada K; Ozaki A; Saito H; Sawano T; Yamamoto K; Murayama A; Senoo Y; Tanimoto T
    Health Policy; 2021 Mar; 125(3):320-326. PubMed ID: 33386174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.